Melanoma treatment in review

被引:497
作者
Domingues, Beatriz [1 ,2 ,3 ]
Lopes, Jose Manuel [1 ,2 ,4 ,5 ]
Soares, Paula [1 ,2 ,5 ]
Populo, Helena [1 ,2 ]
机构
[1] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Rua Julio Amaral de Carvalho 45, P-4200135 Porto, Portugal
[2] Univ Porto, Inst Invest & Inovacao Saude, Porto, Portugal
[3] Univ Porto, Fac Sci, Porto, Portugal
[4] Hosp Sao Joao, Dept Pathol, Porto, Portugal
[5] Univ Porto, Med Fac, Dept Pathol, Porto, Portugal
来源
IMMUNOTARGETS AND THERAPY | 2018年 / 7卷
关键词
cancer; melanoma; therapy; targets;
D O I
10.2147/ITT.S134842
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient's health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.
引用
收藏
页码:35 / 49
页数:15
相关论文
共 161 条
  • [1] Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition
    Abildgaard, Cecilie
    Dahl, Christina
    Basse, Astrid L.
    Ma, Tao
    Guldberg, Per
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [2] CAR T Cell Therapy: A Game Changer in Cancer Treatment
    Almasbak, Hilde
    Aarvak, Tanja
    Vemuri, Mohan C.
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [3] American Cancer Society, 2017, CANC FACTS FIG 2017
  • [4] Andtbacka RHI, 2013, J CLIN ONCOL, V31
  • [5] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    Ascierto, Paolo A.
    Schadendorf, Dirk
    Berking, Carola
    Agarwala, Sanjiv S.
    van Herpen, Carla M. L.
    Queirolo, Paola
    Blank, Christian U.
    Hauschild, Axel
    Beck, J. Thaddeus
    St-Pierre, Annie
    Niazi, Faiz
    Wandel, Simon
    Peters, Malte
    Zubel, Angela
    Dummer, Reinhard
    [J]. LANCET ONCOLOGY, 2013, 14 (03) : 249 - 256
  • [6] Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
    Atefi, Mohammad
    von Euw, Erika
    Attar, Narsis
    Ng, Charles
    Chu, Connie
    Guo, Deliang
    Nazarian, Ramin
    Chmielowski, Bartosz
    Glaspy, John A.
    Comin-Anduix, Begonya
    Mischel, Paul S.
    Lo, Roger S.
    Ribas, Antoni
    [J]. PLOS ONE, 2011, 6 (12):
  • [7] Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
    Attia, P
    Maker, AV
    Haworth, LR
    Rogers-Freezer, L
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 582 - 592
  • [8] Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review
    Austin, Evan
    Mamalis, Andrew
    Ho, Derek
    Jagdeo, Jared
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2017, 309 (04) : 229 - 242
  • [9] Baldea I, 2012, J PHYSIOL PHARMACOL, V63, P109
  • [10] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545